Effect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery
- Conditions
- Malnutrition
- Interventions
- Dietary Supplement: nutritional supplementOther: general nutritional informationOther: individualized nutritional guidelines
- Registration Number
- NCT04926597
- Lead Sponsor
- Philipp Schuetz
- Brief Summary
This study is to compare the sustained post-discharge nutritional support to reach individual energy and protein goals to usual care home nutrition in medical patients at nutritional risk.
- Detailed Description
Malnutrition is a strong and independent long-term risk factor for mortality, rehospitalisation and functional decline, particularly in the elderly, polymorbid medical patient population. The randomized-controlled Effect of early nutritional support on Frailty, Functional Outcomes and Recovery of malnourished medical inpatients Trial (EFFORT, Lancet 2019) included 2028 patients in eight Swiss hospitals and found that nutritional support during the inhospital stay reduces very efficiently the risk for complications and mortality with numbers needed to treat (NNT) of 23 and 37, respectively.
Yet, the nutritional intervention was not continued after hospital discharge of patients and long-term follow-up data of patients showed a lack of sustained effect of the initial nutritional support strategy. There is a current lack of trial data investigating whether long-term use of nutritional support has a sustained effect on clinical outcomes in this patient population. This study is to compare the continuous use of nutritional support with the use of approved oral nutritional supplements to reach protein and energy goals and to analyze whether medical patients at nutritional risk show a sustained benefit from long-term nutritional support after hospital discharge, and why and how nutritional support affects the course of disease from a mechanistic physio-pathological standpoint.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1200
- Informed Consent as documented by signature
- Adult (age ≥18 years), medical patients
- Nutritional risk screening using the Nutritional Risk Screening (NRS): total score ≥3 points consisting of ≥1 points for impairment of the nutritional status [weight loss >5% in 3 month or food intake of 50-75% in the last week before hospital admission] plus ≥1 for the severity of the disease (i.e., cancer, chronic kidney disease, chronic heart failure, COPD) and other chronic diseases according to the definition of the "National Center for Chronic Disease Prevention and Health Promotion": Chronic diseases are defined broadly as conditions that last 1 year or more and require ongoing medical attention or limit activities of daily living or both .
- after surgery
- unable to ingest oral nutrition
- need for long-term nutrition,
- terminal condition
- acute pancreatitis or acute liver failure
- patients discharged to a nursing home
- patients unlikely to comply with nutritional support treatment (e.g., dementia)
- COVID-Hospitalisation requiring intensive care
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention group: individualized nutritional support individualized nutritional guidelines Intervention group patients will receive individualized nutritional support to reach energy and protein goals with the support of an experienced, unblinded dietician and with use of oral nutritional supplements (ONS) as needed Intervention group: individualized nutritional support nutritional supplement Intervention group patients will receive individualized nutritional support to reach energy and protein goals with the support of an experienced, unblinded dietician and with use of oral nutritional supplements (ONS) as needed Control group: general information on healthy food habits general nutritional information Control group patients will receive nutritional counselling (general information on healthy food habits) at discharge, but no nutritional support strategy will be used during follow-up
- Primary Outcome Measures
Name Time Method time to death from any cause (i.e., all-cause mortality) Enrollment to 3 years time to death from any cause (i.e., all-cause mortality)
- Secondary Outcome Measures
Name Time Method Time to non-elective hospital readmission after discharge from the index hospital stay assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)] Time to non-elective hospital readmission after discharge from the index hospital stay
Time to the first major complication assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)] time to the first major complication including death, bacterial infection with need for antibiotic treatment, major cardiovascular event (i.e., stroke, intracranial bleeding, cardiac arrest, myocardial infarction) or pulmonary embolism, acute renal failure, gastro-intestinal events (including hemorrhage, intestinal perforation, acute pancreatitis)
Changes in functional status measured by the Barthel's index assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)] Changes in functional status measured by the Barthel's index (scores range from 0 to 100, with higher scores indicating better functional status)
Changes in quality of life measured with the European Quality of Life 5 Dimensions index (German Version, EQ-5D index) assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)] Changes in quality of life measured with the European Quality of Life 5 Dimensions index (German Version, EQ-5D index values range from 0 to 1, with higher scores indicating better quality of life)
Changes in quality of life measured with the visual-analogue scale (EQ-5D VAS) assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)] Changes in quality of life measured with the visual-analogue scale (EQ-5D VAS) (scores range from 0 to 100, with higher scores indicating better health status).
Trial Locations
- Locations (18)
Hospital Universitari Vall Hebron de Barcelona
🇪🇸Barcelona, Spain
Hospital Universitario de Getafe
🇪🇸Getafe, Spain
Complejo AComplejo Asistencial Universitario de León
🇪🇸León, Spain
Hospital U. Gregorio Marañón de Madrid
🇪🇸Madrid, Spain
Hospital Universitario Regional de Málaga
🇪🇸Málaga, Spain
Hospital Clínico Universitario de Valladolid
🇪🇸Valladolid, Spain
Spital Zofingen
🇨🇭Zofingen, Aargau, Switzerland
Spital Emmental Burgdorf
🇨🇭Burgdorf, Bern, Switzerland
Spital Thun
🇨🇭Thun, Bern, Switzerland
Spital Lachen
🇨🇭Lachen, Schwyz, Switzerland
Kantonsspital Münsterlingen
🇨🇭Münsterlingen, Thurgau, Switzerland
Kantonsspital Aarau, University Department of Internal Medicine
🇨🇭Aarau, Switzerland
Bern University Hospital, Department of General Internal Medicine
🇨🇭Bern, Switzerland
Kantonsspital Lucerne, Department of Internal Medicine
🇨🇭Lucerne, Switzerland
Kantonsspital Sankt Gallen
🇨🇭Sankt Gallen, Switzerland
Klinik Hirslanden Zürich
🇨🇭Zürich, Switzerland
Stadtspital Zürich
🇨🇭Zürich, Switzerland
Universitätsspital Zürich
🇨🇭Zürich, Switzerland